By API User
Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options • Additional funding results in a pro forma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a … Continued
By API User
Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR … Continued
By API User
Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on … Continued
By API User
10 December 2025 – Brisbane, Australia | LTR Pharma Limited (ASX:LTP) has today announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) to commence its clinical trial activities for a Phase II clinical study for its nasal erectile dysfunction treatment SPONTAN®. This follows confirmation and acceptance of the Company’s Clinical Trial Notification … Continued
By API User
Highlights• University of Miami (UMiami) commences clinical use of CT:VQ™ • UMiami becomes second U.S. academic medical centre (AMC) after Stanford to begin clinical use of CT:VQ™, validating early commercialisation strategy • Arrangement provides three months of introductory pricing prior to full commercial terms• Lahey Hospital & Medical Center signs two-year agreement for IQ-UIP™ Melbourne, Australia, … Continued
By API User
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, … Continued
By API User
Evinco Therapeutics is an Australian start-up on a mission to transform the treatment of Alzheimer’s disease and other neuroinflammatory conditions Melbourne, Australia, 4 December 2025 – An exciting chapter in medical innovation begins today with the official launch of Evinco Therapeutics Pty Ltd (“Evinco” or “Company”), a Melbourne-based biotechnology company developing advanced immune-based therapies … Continued
By API User
Highlights• Philips will add CT:VQ™ to its North American product catalogue, backed by minimum contractual order commitment of approximately A$15m (US$10m) over two years • CT:VQ™ sales via Philips will be on full commercial terms • Philips to deploy dedicated sales and clinical specialists with CT:VQ™ targets across United States and Canada • Commercial launch … Continued
By API User
3 December 2025 – Perth, Australia | Nexsen Limited (ASX:NXN) has today announced the appointment of internationally recognised surgeon-scientist, Professor Shekhar Kumta, as a Non-Executive Director. Professor Kumta brings more than 45 years’ experience across Australia and Hong Kong, with senior faculty, hospital governance and medical leadership roles spanning major institutions including the Chinese University … Continued
By API User
Delegates from Australia and around the world have convened in Melbourne as the city’s biomedical and health innovation precincts take the spotlight, including the Monash Technology Precinct (MTP), Victoria’s largest employment hub outside the CBD. This is the first time Melbourne has hosted the annual National Health and Innovation Precincts Summit. As Australia’s leading biomedical hub … Continued
